Management of Early Breast Cancer

Objectives

Provide evidence-based, best-practice guidance for health-care practitioners, policy-makers and consumers making decisions on early breast cancer management in New Zealand, while supporting rather than replacing clinical judgement for individual cases.[1]Promote high-quality, clinically effective and nationally consistent care across diagnosis, treatment and follow-up for ductal carcinoma in situ and invasive breast adenocarcinoma at stages I, II and IIIA, including men where clinically applicable.[2]

• Improve cancer outcomes and reduce inequalities in line with the New Zealand Cancer Control Strategy, spanning screening, early detection, diagnosis, treatment, rehabilitation, support and palliative care.[3]
• Advance equity by applying Treaty of Waitangi principles of partnership, participation and protection, addressing Māori health needs throughout guideline development, and recognising disparities affecting Māori and Pacific women.[2][4][3]
• Support informed, individualised decisions by providing information suited to each woman’s educational, cultural and ethnic circumstances, including clear explanation of treatment options, benefits, risks, support services and follow-up.[5][6]
• Deliver patient-centred care that addresses psychological, physical, social, practical, cultural and family or whānau needs alongside cancer treatment.[7][8]
• Manage women through multidisciplinary care, using coordinated expert input to support diagnosis, treatment selection, consistent information and continuity across the clinical pathway.[5][9]
• Guide evidence-graded clinical care across staging, surgery, reconstruction, radiotherapy, systemic therapy, endocrine therapy, surveillance, genetic assessment and risk-reducing treatment.[10][11][12]
• Promote appropriate local treatment by offering eligible women a choice between breast-conserving surgery with radiotherapy and mastectomy, with complete tumour excision, clear margins and acceptable cosmetic outcomes.[13][14][15]
• Reduce avoidable recurrence and treatment harm through risk-adapted radiotherapy, systemic treatment, axillary assessment, bone-health protection and long-term follow-up.[16][17][18][19]

Implementation

Develop the guideline through systematic review of international evidence interpreted for the New Zealand context, supplemented where necessary by non-systematic reviews, expert consensus and consultation feedback.[1][20]The Ministry of Health commissioned the guideline under the New Zealand Cancer Control Strategy Action Plan 2005–2010, while the New Zealand Guidelines Group researched and drafted it independently of the Ministry.[1][2]

• Structure recommendations around 44 prioritised clinical questions, selected for their importance to patients, uncertainty, controversy and variation in practice, and assess outcomes including survival, recurrence, quality of life and adverse effects.[21][22]
• Use the New Zealand Guidelines Group’s three-step process to appraise studies, weigh the body of evidence and formulate recommendations; use consensus-derived good practice points where evidence is unavailable.[23][24]
• Apply formal appraisal tools, including the Appraisal of Guidelines for Research and Evaluation instrument, Quality Assessment of Diagnostic Accuracy Studies tool and Scottish Intercollegiate Guidelines Network checklists, and assess evidence quality, volume, consistency, applicability and clinical impact through evidence tables and Considered Judgment Forms.[25][20][23]
• Grade recommendations according to evidence strength rather than importance, using grades A, B, Cc and I, alongside good practice points where appropriate.[5][23]
• Engage a multidisciplinary Guideline Development Team comprising clinical, nursing, primary-care, epidemiological, radiological, oncology, genetics, consumer, Māori, Pacific and BreastScreen Aotearoa representation; involve consumers in defining questions, reviewing evidence and developing recommendations.[2][4][24][26]
• Undertake stakeholder consultation, including five face-to-face Guideline Development Team meetings and external peer review circulated to 317 individuals and organisations in 2008.[4][24]
• Deliver care through multidisciplinary team meetings in which all relevant specialists participate, the woman’s views inform management, decisions are recorded in the medical record and outcomes are communicated to her.[27]
• Assign an identified care coordinator, such as a breast care nurse or breast physician, to facilitate the treatment pathway, provide information and support, and identify psychosocial needs from diagnosis through follow-up.[27]
• Provide culturally safe services by using professional interpreters where required, allowing time for whānau or family involvement, supporting Māori and Pacific providers and workforce development, and improving ethnicity-data quality for service planning and evaluation.[28][29]
• Use clinical pathways that include history and examination-based staging, selective imaging, pathology quality assurance, shared treatment decisions, timely treatment, specialist referral and surveillance mammography.[30][31][32][19]
• Monitor selected clinical processes and outcomes, including adherence to recommendations, treatment timeliness, pathology and HER2 quality assurance, cardiac function during trastuzumab, bone density during endocrine treatment, recurrence and survival outcomes.[2][33][34][32][35]
• Use national cancer registration and mortality data to monitor incidence, survival, stage and ethnic disparities; statutory reporting supports completeness of the New Zealand Cancer Registry.[3]

Monitoring & Evaluation

Monitoring is primarily embedded in clinical care, evidence appraisal and national cancer surveillance rather than in a single implementation performance framework. The guideline calls for adherence to recommendations to be monitored, but does not define a comprehensive national indicator set, reporting timetable or formal accountability mechanism.[2]

• Use the New Zealand Cancer Registry, administered by the New Zealand Health Information Service, to record new primary malignant cancers by site, stage, pathology, age, gender and ethnicity.[3]Maintain registry completeness through statutory laboratory reporting under the Cancer Registry Act 1993 and Cancer Registry Regulations 1994, supplemented by hospital discharge, death-certificate and autopsy reports.[3]
• Monitor breast cancer incidence, mortality, survival, stage and ethnic inequities through national registration and mortality data. In 2005, the source records 2,458 female registrations, 647 female deaths and approximately 82% five-year cumulative survival.[12]
• Apply BreastScreen Aotearoa quality standards under which 90% of women should normally receive first surgical treatment within 20 working days of final diagnostic results.[33]Reported performance was 57.7% for Māori women and 71.2% for non-Māori women.[33]
• Improve ethnicity-data reliability through consistent collection practices, systematic analysis and current Ministry of Health protocols.[29]Account for historical undercounting in Māori cancer data, estimated at about 17% for registrations and 6% for deaths during 1996–2001.[29]
• Use multidisciplinary team meetings to document management decisions, record adjuvant-treatment decisions and communicate outcomes to women.[27][36]
• Monitor treatment-specific outcomes, including recurrence, survival, treatment toxicity and quality of life, where relevant to the intervention.[21]Monitor cardiac function regularly, for example every three months, during trastuzumab treatment using Multi Gated Acquisition scans or echocardiography.[34]
• Monitor bone density at least every two years after baseline spine and hip dual energy X-ray absorptiometry for women with premature menopause or receiving an aromatase inhibitor, with frequency tailored to individual risk.[35]
• Provide annual mammographic surveillance after the first post-treatment mammogram, undertaken one year after the first diagnostic mammogram or six months after radiotherapy.[37]Focus routine follow-up on physical examination and mammography rather than intensive laboratory or instrumental testing in asymptomatic women.[19][37]
• Maintain pathology and laboratory quality assurance through structured reporting, external quality-assurance participation, and standardised hormone-receptor and human epidermal growth factor receptor 2 testing.[38][39]
• Grade recommendations according to the strength and quality of the supporting evidence, rather than their importance, using the New Zealand Guidelines Group process.[23][24]

Clinical evidence evaluation is extensive, including systematic reviews, formal study appraisal, evidence tables, Considered Judgment Forms, expert consensus where evidence is absent, and peer review of the draft by 317 individuals and organisations in 2008.[20][23][24]However, the source does not specify a unified implementation audit programme, routine public reporting process, named body accountable for compliance, or sanctions for non-adherence.[2][23][24]

Costing & Financing

Financing information is limited: the guideline development process was funded by the Ministry of Health, while the clinical recommendations were not based on cost-effectiveness analysis or quality-adjusted life years.[1][2]The evidence-search process excluded studies investigating cost effectiveness.[20]

• Provide publicly funded mammography through BreastScreen Aotearoa for eligible women aged 45 to 69 years from 1 July 2004.[3]The source does not specify the programme budget, unit costs or total expenditure.[3]
• Recognise that multidisciplinary care was considered an efficient and cost-effective means of caring for women with breast cancer, although no quantified economic evaluation or budget is provided.[40]
• Recognise treatment-related travel, inconvenience and separation from support networks as resource burdens associated with radiotherapy.[41][42]
• Consider financial and indirect barriers affecting Māori access to care, including prescription charges, general-practitioner house-call costs, lost wages, travel and childcare-related constraints.[43]
• Recognise that patients generally contribute towards primary-care costs in New Zealand, which may create a financial barrier to general-practitioner-led follow-up and widen ethnic or socioeconomic inequities.[44]
• Recognise that alternative follow-up models may reduce patients’ time and costs and were considered more economical than routine specialist follow-up, without a quantified economic evaluation.[45][44]
• Consider the financial costs of prolonged endocrine therapy alongside its benefits, adverse effects and toxicities.[46][47]
• Resource Māori-specific cancer services, Pacific support groups, culturally appropriate psychosocial support, and Māori and Pacific workforce development, although no allocations, funding sources or quantified gaps are specified.[28][29]

No overall implementation budget, treatment-cost schedule, funding-gap estimate, resource-mobilisation plan, economic assumptions or costed workforce plan is specified for the guideline or wider cancer-control action.[12][3][20]Financial declarations by contributors record sponsorship, conference support, shareholdings, advisory-board fees and consultancy fees, but no monetary amounts.[26][48]